Jacques Van Gompel, PhD has more than 30 years of experience in Genetic Toxicology in the chemical and pharmaceutical industry setting. After studies in Cell Biology & Genetics at the Free University of Brussels (1987), Jacques Van Gompel was appointed a position as research assistant within the dept. of Experimental Pathology at the University Hospital (AZ-VUB). In 1992 he joined the Janssen Research Foundation and until February 2000 he was Study Director for the bacterial and mammalian gene mutation assays within the dept. of Genetic Toxicology. Meanwhile he also obtained his PhD at the VUB on the topic of “Development, Evaluation and Implementation of Acute and Chronic in vitro Exposure Methods in Applied Genetic Toxicology”. In 2000 he became responsible for the genetic toxicology profiling within the newly formed dept. of Exploratory Development. Jacques combined this with a role as ADME/TOX representative for discovery projects in the areas of CNS, Oncology and Infectious diseases from Hit-to-Lead until delivery into the Preclinical Development Organization. In 2005 he became Head of the dept of Genetic and in vitro Toxicology within the Global PreClinical Development organization with end-to-end responsibilities from Hit-to-Lead until brand support for high throughput genotoxicity screening and genotoxic/mutagenic impurities, cleaning validation, PbOEL calculations. Since 2005, Jacques performed also the expert review for all Impurity management reports at Janssen. He was the main user of Lhasa (DEREK, SARAH & VITIC), Leadscope (Instem) and Multicase software. Jacques was an ICH M7 expert workgroup observer for CEFIC/APIC until 2023. Jacques was member of the Global Impurity Steering Team and the Genotox Review Committee at Janssen. 

MoonWave B.V. is a trusted partner of D2team
JackyVanGompel@d2team.eu